Soliris franchise expansion and progress of orphan-focused pipeline add depth to ALXN’s narrow moat.
Grifols' narrow moat stems from its scale and expertise in plasma protein processing.
The company's flagship Budweiser brand is facing meaningful headwinds in the United States from craft brewers, spirits companies, and persistently high levels of unemployment.The European beer market is much more fragmented than that of the Americas, and significant retailer and pub consolidation
Shire's narrow moat is supported by specialty pharma expertise and a growing rare-disease business.
Jakafi's monopoly extended as competing myelofibrosis drug is discontinued.
Revlimid still supports Celgene's narrow moat, but Pomalyst and Abraxane are diversifying sales.
Cystic fibrosis clinical trial results in 2014 are critical for Vertex’s future moat potential.
Optimer and Trius acquisitions reduce Cubist's uncertainty post-Cubicin patent expiration.
Continued expansion of Adcetris' indications and pipeline progress underpin a positive moat trend.
Alnylam is in the early stages of building a moat around its RNA-based drug platform.